FCER2 antibody

Catalog No. ABIN2658121

Product Details anti-FCER2 Antibody

Target: FCER2 (Fc Fragment of IgE, Low Affinity II, Receptor For (CD23) (FCER2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FCER2 antibody is un-conjugated

Application: Flow Cytometry (FACS), ELISA, Immunofluorescence (IF)

Purification: The antibody was purified by affinity chromatography.

Clone: EBVCS-5

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C

Target Details for FCER2

Target: FCER2 (Fc Fragment of IgE, Low Affinity II, Receptor For (CD23) (FCER2))

Alternative Name: CD23 (FCER2 Products)

Synonyms: BLAST-2 antibody, CD23 antibody, CD23A antibody, CLEC4J antibody, FCE2 antibody, IGEBF antibody, Fcer2a antibody, Fc fragment of IgE receptor II antibody, FCER2 antibody, Fcer2 antibody

Background: CD23 is a 45 kD protein, also known as Leu-20, FcεRII, IgE Fc receptor, BLAST-2, B6, and low affinity IgE receptor. It is a member of the Ig family, expressed on most mature B cells, B cells in follicular mantle (but not in proliferating germinal center cells, follicular dendritic cells, monocytes, eosinophils, Langerhans cells, and a subset of T cells (10-15 % of tonsillar T cells). CD23 responds to high levels of IgE by downregulating IgE secretion. In human monocytes, CD23 triggering results in release of pro-inflammatory cytokines including TNF-α, IL-1, IL-6, and GM-CSF. CD23 can be proteolytically cleaved to generate soluble CD23 fragments of various molecular weights. In chronic lymphocytic leukemia, levels of soluble CD23 in the serum can be used as a prognostic marker to identify patients at high risk for disease progression. Alternate splicing of exon 2 can also generate two cell-surface isoforms of CD23 differing by 6 amino acids in their cytoplasmic region.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process